These putative in silico predicted binding modes of the two compounds in clinical trials offer new insights and real value to the RAS drug discovery community. While a co-crystal structure would be preferable these predicted binding modes offer valuable data for potential future improvements and understanding for rational drug design in the SII-P. If and when these co-crystal structures are solved, this could potentially verify how accurate predictions of this type can be with unbiased MD simulations with starting configurations based on analogous structures. This would be very important for understanding the power of microsecond timescale simulations or is even longer timescales required for this type of studies, both for KRAS and more broadly across rational drug design.